Endo issued subpoena regarding Lidoderm promotion

Share this article:
Endo Pharmaceuticals was issued a subpoena by the Department of Health and Human Services regarding the promotion of its post-shingles pain patch Lidoderm, requesting documents from 1999 to the present related to the company's knowledge of off-label uses for the treatment.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.